NKARTA Reports Q4 Basic EPS of USD -0.37
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Should l Buy NKTX?
Source: moomoo
Market Overview: The article discusses the current state of the market, highlighting key trends and movements in various sectors.
Economic Indicators: It emphasizes the importance of recent economic indicators that are influencing market performance and investor sentiment.
Investment Strategies: The piece outlines potential investment strategies that could be beneficial in the current economic climate.
Future Outlook: It concludes with predictions about future market developments and factors that could impact growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTX
Wall Street analysts forecast NKTX stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.420
Low
10.00
Averages
12.33
High
16.00
Current: 2.420
Low
10.00
Averages
12.33
High
16.00
About NKTX
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nkarta Reaches Agreement with FDA to Optimize Clinical Trials for NKX019
- Patient Burden Reduction: Nkarta's agreement with the FDA allows outpatient administration of NKX019 at community research centers, significantly reducing the need for overnight stays and enhancing treatment accessibility for patients.
- Redosing Flexibility: The option to re-dose participants in both Ntrust-1 and Ntrust-2 studies will help optimize individual treatment responses, thereby increasing the overall effectiveness of the clinical trials.
- Expanded Indication: The addition of rheumatoid arthritis patients to the Ntrust-2 study broadens the scope to address this autoimmune disease with significant unmet needs, likely attracting more participants and enhancing the trial's relevance.
- Clinical Trial Progress: The final amendments for Ntrust-1 and Ntrust-2 have been submitted for FDA and IRB approval, which is expected to accelerate the clinical development of NKX019 and strengthen the company's competitive position in the autoimmune disease market.
See More
Nkarta Reaches FDA Agreement to Optimize Clinical Trials
- Protocol Change: Nkarta has reached an agreement with the U.S. FDA to allow outpatient dosing of its lead asset NKX019, reducing patient monitoring time from 24 hours to just 2 hours, significantly lowering patient burden and expanding access to treatment.
- Trial Design Optimization: The Ntrust-1 and Ntrust-2 clinical trials will no longer require overnight stays, allowing community research centers and rheumatologists to administer NKX019 in outpatient settings, further alleviating the overall treatment burden on trial subjects.
- Positive Market Reaction: Following the announcement, Nkarta's stock rose approximately 13%, reflecting market optimism regarding the company's clinical trial advancements and recognition of the new treatment protocol, which may enhance investor confidence.
- Data Presentation Plans: Nkarta is on track to present initial data from the Ntrust-1 and Ntrust-2 trials at a medical conference this year, which is expected to further bolster the company's market position in the autoimmune disease sector.
See More
Nkarta Files $350M Mixed-Securities Offering to Fund Growth
- Funding Initiative: Nkarta has filed a $350 million mixed-securities registration with the SEC, planning to sell up to $100 million in common stock through an ATM deal with Stifel, Nicolaus & Company to support its funding needs.
- Commission Structure: Stifel may earn up to a 3% commission on the shares sold, which will impact Nkarta's financing costs while providing Stifel with an additional revenue stream.
- Use of Proceeds: The net proceeds from this offering will be allocated to R&D, manufacturing, working capital, capital expenditures, and general corporate purposes, including strategic investments aimed at enhancing the company's market competitiveness and innovation capabilities.
- Future Sales Opportunities: Any unsold portion of the $100 million will be available for future sales under the base prospectus, providing Nkarta with flexible financing options to adapt to changing market demands.
See More
Nkarta Q4 Earnings Miss Expectations
- Earnings Performance: Nkarta reported a Q4 GAAP EPS of -$0.37, missing the expected -$0.32, indicating challenges in profitability that could affect investor confidence moving forward.
- Cash Position: As of December 31, 2025, Nkarta had cash, cash equivalents, restricted cash, and marketable securities totaling $295.1 million, suggesting a reasonable liquidity cushion, but future capital efficiency will be crucial.
- Market Reaction: The earnings miss may put downward pressure on Nkarta's stock price, prompting investors to closely monitor subsequent financial performance and management's strategic responses.
- Future Outlook: Despite the current disappointing financial data, Nkarta must develop effective strategies to enhance profitability and strengthen its competitive position, particularly in the rapidly evolving biopharmaceutical sector.
See More
NKARTA REPORTS Q4 NET LOSS OF USD 27.408 MILLION
- Financial Performance: The company reported a net income of USD 27.408 million.
- Quarterly Results: This figure reflects the financial results for the recent quarter.
See More
NKARTA Reports Q4 Basic EPS of USD -0.37
Market Overview: The article discusses the current state of the market, highlighting key trends and movements in various sectors.
Economic Indicators: It emphasizes the importance of recent economic indicators that are influencing market performance and investor sentiment.
Investment Strategies: The piece outlines potential investment strategies that could be beneficial in the current economic climate.
Future Outlook: It concludes with predictions about future market developments and factors that could impact growth.
See More
Nkarta Reaches Agreement with FDA to Optimize Clinical Trials for NKX019
- Patient Burden Reduction: Nkarta's agreement with the FDA allows outpatient administration of NKX019 at community research centers, significantly reducing the need for overnight stays and enhancing treatment accessibility for patients.
- Redosing Flexibility: The option to re-dose participants in both Ntrust-1 and Ntrust-2 studies will help optimize individual treatment responses, thereby increasing the overall effectiveness of the clinical trials.
- Expanded Indication: The addition of rheumatoid arthritis patients to the Ntrust-2 study broadens the scope to address this autoimmune disease with significant unmet needs, likely attracting more participants and enhancing the trial's relevance.
- Clinical Trial Progress: The final amendments for Ntrust-1 and Ntrust-2 have been submitted for FDA and IRB approval, which is expected to accelerate the clinical development of NKX019 and strengthen the company's competitive position in the autoimmune disease market.
See More
Nkarta Reaches FDA Agreement to Optimize Clinical Trials
- Protocol Change: Nkarta has reached an agreement with the U.S. FDA to allow outpatient dosing of its lead asset NKX019, reducing patient monitoring time from 24 hours to just 2 hours, significantly lowering patient burden and expanding access to treatment.
- Trial Design Optimization: The Ntrust-1 and Ntrust-2 clinical trials will no longer require overnight stays, allowing community research centers and rheumatologists to administer NKX019 in outpatient settings, further alleviating the overall treatment burden on trial subjects.
- Positive Market Reaction: Following the announcement, Nkarta's stock rose approximately 13%, reflecting market optimism regarding the company's clinical trial advancements and recognition of the new treatment protocol, which may enhance investor confidence.
- Data Presentation Plans: Nkarta is on track to present initial data from the Ntrust-1 and Ntrust-2 trials at a medical conference this year, which is expected to further bolster the company's market position in the autoimmune disease sector.
See More
Nkarta Files $350M Mixed-Securities Offering to Fund Growth
- Funding Initiative: Nkarta has filed a $350 million mixed-securities registration with the SEC, planning to sell up to $100 million in common stock through an ATM deal with Stifel, Nicolaus & Company to support its funding needs.
- Commission Structure: Stifel may earn up to a 3% commission on the shares sold, which will impact Nkarta's financing costs while providing Stifel with an additional revenue stream.
- Use of Proceeds: The net proceeds from this offering will be allocated to R&D, manufacturing, working capital, capital expenditures, and general corporate purposes, including strategic investments aimed at enhancing the company's market competitiveness and innovation capabilities.
- Future Sales Opportunities: Any unsold portion of the $100 million will be available for future sales under the base prospectus, providing Nkarta with flexible financing options to adapt to changing market demands.
See More
Nkarta Q4 Earnings Miss Expectations
- Earnings Performance: Nkarta reported a Q4 GAAP EPS of -$0.37, missing the expected -$0.32, indicating challenges in profitability that could affect investor confidence moving forward.
- Cash Position: As of December 31, 2025, Nkarta had cash, cash equivalents, restricted cash, and marketable securities totaling $295.1 million, suggesting a reasonable liquidity cushion, but future capital efficiency will be crucial.
- Market Reaction: The earnings miss may put downward pressure on Nkarta's stock price, prompting investors to closely monitor subsequent financial performance and management's strategic responses.
- Future Outlook: Despite the current disappointing financial data, Nkarta must develop effective strategies to enhance profitability and strengthen its competitive position, particularly in the rapidly evolving biopharmaceutical sector.
See More
NKARTA REPORTS Q4 NET LOSS OF USD 27.408 MILLION
- Financial Performance: The company reported a net income of USD 27.408 million.
- Quarterly Results: This figure reflects the financial results for the recent quarter.
See More
NKARTA Reports Q4 Basic EPS of USD -0.37
Market Overview: The article discusses the current state of the market, highlighting key trends and movements in various sectors.
Economic Indicators: It emphasizes the importance of recent economic indicators that are influencing market performance and investor sentiment.
Investment Strategies: The piece outlines potential investment strategies that could be beneficial in the current economic climate.
Future Outlook: It concludes with predictions about future market developments and factors that could impact growth.
See More
